ArticleJournal of translational medicine2018
Oral Escherichia coli expressing IL-35 meliorates experimental colitis in mice.
Article in Journal of translational medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.
- The Role of Genetically Engineered Probiotics for Treatment of Inflammatory Bowel Disease: A Systematic Review.Nutrients · 2023Pooled it
- Engineered Bacteroides thetaiotaomicron sense gut inflammation and deliver therapeutic molecules to alleviate colitis in mice.Nature microbiology · 2026Article
- Interleukin-35 as a key immunoregulatory mediator in steroid-hyporesponsive severe asthma.Frontiers in immunology · 2026Review
- Microbial allies in skin trauma recovery: from immune modulation to engineered probiotic therapeutics.Burns & trauma · 2026Review
- Gut Microbiota Modulation in IBD: From the Old Paradigm to Revolutionary Tools.International journal of molecular sciences · 2025Review
- Genetically engineered bacteria as inflammatory bowel disease therapeutics.Engineering microbiology · 2024Review
- Recent advances in bacteria-based platforms for inflammatory bowel diseases treatment.Exploration (Beijing, China) · 2024Review
- The Role of the Gut Microbiome in Inflammatory Bowel Disease: The Middle East Perspective.Journal of personalized medicine · 2024Article
- Engineering bacterial warriors: harnessing microbes to modulate animal physiology.Current opinion in biotechnology · 2024Review
- Engineered microorganisms: A new direction in kidney stone prevention and treatment.Synthetic and systems biotechnology · 2024Review
- Upregulation of TCPTP in Macrophages Is Involved in IL-35 Mediated Attenuation of Experimental Colitis.Mediators of inflammation · 2024Article
- Exploring the Plasticity of Diet on Gut Microbiota and Its Correlation with Gut Health.Nutrients · 2023Article
- Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives.World journal of gastroenterology · 2023Review
- Houttuynia cordata thunb. alleviates inflammatory bowel disease by modulating intestinal microenvironment: a research review.Frontiers in immunology · 2023Review
- Role of adherent invasiveWorld journal of clinical cases · 2022Review
- Next-Generation Probiotics for Inflammatory Bowel Disease.International journal of molecular sciences · 2022Review
- Traditional Chinese Medicine Regulates Th17/Treg Balance in Treating Inflammatory Bowel Disease.Evidence-based complementary and alternative medicine : eCAM · 2022Review
- Genetically engineered bacterium: Principles, practices, and prospects.Frontiers in microbiology · 2022Review
- Endometrial Regenerative Cell-Derived Conditioned Medium Alleviates Experimental Colitis.Stem cells international · 2022Article
- Interleukin-35: Structure, Function and Its Impact on Immune-Related Diseases.Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundUlcerative colitis (UC) is a type of inflammatory bowel disease (IBD) characterized by chronic inflammation of colon. It is commonly believed that the imbalance of immune system and overwhelming production of cytokines are involved in the pathogenesis of UC. Recent studies demonstrated that interleukin-35 (IL-35), a key player in the regulation of inflammation, has been identified as potential therapeutic target to treat UC. However, conventional intravenous administration is costly and inconvenient. The present study was designed to establish a novel IL-35 delivery system and investigate its therapeutic effects on dextran sulfate sodium (DSS)-induced experimental colitis in mice for the first time.
methodsAn engineered Escherichia coli (E. coli/IL-35) expressing IL-35 was constructed. Adult male BALB/c mice randomly got the oral administration of E. coli/IL-35, empty plasmid-transformed E. coli (E. coli0) or PBS for treatment following ingestion of 3% DSS solution for 5 days. Normal mice were used as control group. Colonic and splenic tissues were collected on day 10 post-DSS-induction. Clinical signs, disease activity index (DAI), pathological and immunohistological changes, cytokine profiles and cell populations were evaluated.
resultsIntragastric administration of E. coli/IL-35 effectively protected the colitis mice from DSS assimilation including weight loss and colon shortening. Pathological analysis showed significantly lower DAI score and much less intra-colon infiltration of neutrophils and CD3
conclusionsOur study showed that E. coli/IL-35 as a novel oral IL-35 delivery system alleviated inflammatory damage of colonic tissue in the colitic mice. Genetic therapeutic strategies using engineered E. coli encoding immunoregulatory cytokines may provide a potential approach for the treatment of IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.